Study S002354

A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea.

ClinicalTrials.gov record

Registration

Registration: NCT07018544
Study type: OBSERVATIONAL
Status: ENROLLING_BY_INVITATION
Enrollment: 840
Start: 2024-11-19
Primary completion: 2027-02-28
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity and Overweight
Interventions: OTHER:semaglutide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1281-9419

Registered primary outcomes

Number (incidence) of AEs [From Visit 1 (baseline, 0 week) to Visit 4 (22 weeks < ~ ≤ 30 weeks)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.